Pfizer's oral antiviral drug paxlovid significantly reduces hospital admissions and deaths
among people with covid-19 who are at high risk of severe illness, when compared with …

Covid-19: What is the evidence for the antiviral Paxlovid? | The BMJ Skip to main content
Intended for healthcare professionals Access provided by Google Indexer Subscribe My …

Interim phase III trial results, released through a press release by the drug's manufacturer,
MSD, found that molnupiravir reduced the risk of admission to hospital or death by around …

The antiviral drug molnupiravir reduced the risk of admission to hospital or death by around
50% in non-hospitalised adults who had mild to moderate covid-19 and were at risk of poor …

Covid-19: What is the evidence for the antiviral molnupiravir? | The BMJ Skip to main content
Intended for healthcare professionals Access provided by Google Indexer Subscribe My …

The data show the death rate at 28 days in covid-19 patients taking hydroxychloroquine is
25.7% compared with 23.5% in patients provided with only usual hospital care (hazard ratio …

An advisory panel of experts has voted by 13 to 10 to recommend that the US Food and
Drug Administration should grant an emergency authorisation to Merck's molnupiravir …

Objective To emulate a randomized target trial to estimate the association between the
antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 …

Objective To examine whether treatment with the antiviral agent molnupiravir during the first
five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse …

Abstract The US Food and Drug Administration has authorized clinicians to prescribe
chloroquine and hydroxychloroquine for patients admitted to hospital with covid-19, despite …